V4762
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse
clone FLT-19, tissue culture supernatant
Sinónimos:
Anti-Flt1 Receptor, Anti-VEGF R-1
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
biological source
mouse
conjugate
unconjugated
antibody form
tissue culture supernatant
antibody product type
primary antibodies
clone
FLT-19, monoclonal
contains
15 mM sodium azide
species reactivity
human
technique(s)
immunohistochemistry (frozen sections): 1:100 using human placenta
immunoprecipitation (IP): suitable
indirect ELISA: suitable
microarray: suitable
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... FLT1(2321)
General description
Monoclonal Anti-VEGF Receptor-1 (Flt1 Receptor) (mouse IgG1 isotype) is derived from the FLT-19 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a recombinant extracellular domain of VEGF Receptor-1 (Flt1 Receptor) of human origin. Vascular endothelial growth factor (VEGF), also called vasculotropin (VAS)1 and vascular permeability factor (VPF) 2 is a member of a family of endothelial cell mitogens and angiogenic factors. VEGF is a homodimeric heparin-binding glycoprotein. VEGF binds to two structurally similar receptor tyrosine kinases; Flt15 (fms-like tyrosine kinase 1, also termed VEGF Receptor-1, VEGF-R1) and KDR6 (kinase-insert domain containing receptor, also termed VEGF-R2). Flt1 is predominately expressed in human placenta and human vascular endothelial cells, while KDR is more widely expressed in all vessel-derived endothelial cells but low in human and fetal bovine placenta.
Mouse monoclonal clone FLT-19 anti-Vascular Endothelial Growth Factor Receptor-1 antibody recognizes the extracellular domain of human VEGF Receptor-1 molecule (Flt1 Receptor). The antibody does not recognize VEGF Receptor-2 (KDR), VEGF receptor-3 (sFlt4,) and PDGF-Rβ.
Immunogen
recombinant human extracellular domain of VEGFR-1.
Application
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse has been used in:
- immunofluorescence labelling
- enzyme-linked immunosorbent assay (ELISA)
- immunohistochemistry
- immunoprecipitation
Mouse monoclonal clone FLT-19 anti-Vascular Endothelial Growth Factor Receptor-1 antibody may be used for the localization of VEGF-R1 using various immunochemical assays such as ELISA, immunoblotting, immunocytochemistry, immunohistochemistry, and immunoprecipitation. Antibodies that react specifically with VEGF receptors are useful for the study of the specific differential tissue expression and intracellular localization of the receptor in normal and neoplastic tissue.
Biochem/physiol Actions
The mitogenic activity of VEGF appears to be stimulated by specific VEGF receptors (160-200 kDa) which can be found on the surface of various endothelial cells. VEGF binds to two structurally similar receptor tyrosine kinases; Flt1 (fms-like tyrosine kinase 1, also known as VEGF Receptor-1 (VEGF-R1), and KDR (kinase insert domain containing receptor, also known as VEGF-R2). Studies using KDR and Flt1 stably transfected endothelial cell lines have shown that these two receptors exhibit different affinities to VEGF and mediate different responses. KDR/Flk1 does not respond to placental growth factor (PlGF), a VEGF related growth factor, while Flt1 binds PlGF specifically. Flt1 is predominately expressed in human placenta and human vascular endothelial cells. Both VEGF receptors (KDR and Flt1) are upregulated in human fetal and adult kidney.
Vascular endothelial growth factor (VEGF) stimulates the proliferation of endothelial cells isolated from both small and large vessels.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
signalword
Warning
hcodes
pcodes
Hazard Classifications
STOT RE 2
Storage Class
10 - Combustible liquids
wgk_germany
WGK 3
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Sophie Le Ricousse-Roussanne et al.
Cardiovascular research, 62(1), 176-184 (2004-03-17)
Recent studies have provided increasing evidence that postnatal neovascularization does not rely exclusively on sprouting of preexisting vessels, but also involves bone marrow-derived circulating endothelial precursors (BM-EPCs). Animal studies revealed that neovascularization of ischemic tissue can be enhanced by BM-EPCs
Real-time ligand binding of fluorescent VEGF-A isoforms that discriminate between VEGFR2 and NRP1 in living cells
PeachnCJ, et al.
Cell Chemical Biology, 25(10), 1208- 1218 (2018)
A Sawano et al.
Blood, 97(3), 785-791 (2001-02-07)
Flt-1, also known as vascular endothelial growth factor receptor 1 (VEGFR-1), is a high-affinity tyrosine kinase receptor for VEGF and is expressed almost exclusively on vascular endothelial cells. As an exception, Flt-1 transcript was recently found to be expressed in
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy
Shinkaruk S, et al.
Current Medicinal Chemistry. Anticancer Agents, 3(2), 95-117 (2003)
Chloe J Peach et al.
Cell chemical biology, 25(10), 1208-1218 (2018-07-31)
Fluorescent VEGF-A isoforms have been evaluated for their ability to discriminate between VEGFR2 and NRP1 in real-time ligand binding studies in live cells using BRET. To enable this, we synthesized single-site (N-terminal cysteine) labeled versions of VEGF165a, VEGF165b, and VEGF121a.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico